EX-99.1 2 ueec_ex991.htm PRESS RELEASE ueec_ex991.htm EXHIBIT 99.1 United Health Products Establishes Collaboration to Conduct Clinical Study DARIEN, CT - July 7, 2026 - United Health Products, Inc. (OTCQB: UEEC) today announced an agreement with NAMSA, a global leader in MedTech contract research, whereby NAMSA will serve as Sponsor of a new clinical study of UHP's CelluSTAT Hemostatic Gauze. Consistent with the company's recent proposal to the FDA to have a non-affiliated party oversee a new clinical study, which the FDA approved in March of this year, NAMSA will initially seek an Investigational Device Exemption (IDE) to organize and conduct a study of UHP's neutralized cellulose hemostat technology. Upon completion of the study, UHP will hold an exclusive right of reference to all data from the study to use in a revised Premarket Approval (PMA) application. This plan will allow a study to proceed (subject to granting of the IDE) while UHP works with the FDA to resolve the outstanding Warning Letter. NAMSA is 100% focused on medical device and in vitro diagnostic technologies and its experts have decades of experience in clinical trial management for Class III hemostati…
Open exhibit ↗Current Report · Items 8.01, 9.01 · 8-K
United Health Products, Inc.
UEECOTCEQUITYCurrent
Other Events
Item 8.01. Other Events. On July 7, 2026, United Health Products, Inc. issued a press release announcing an agreement with NAMSA, an established global MedTech contract research organization, whereby NAMSA will serve as regulatory sponsor of a new clinical study of UHP’s CelluSTAT Hemostatic Gauze in connection with our FDA Premarket Approval (PMA) application.…
Press release in this filing
United Health Products Establishes Collaboration to Conduct Clinical Study →Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01.
Other Events.
On July 7, 2026, United Health Products, Inc. issued a press release announcing an agreement with NAMSA, an established global MedTech contract research organization, whereby NAMSA will serve as regulatory sponsor of a new clinical study of UHP’s CelluSTAT Hemostatic Gauze in connection with our FDA Premarket Approval (PMA) application.
A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.
We refer you to the risk factors in Part I, “Item 1A, Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 for a discussion of the risks relating to our Premarket Approval application.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number Description
───────────────────────────────────────────────────────────────────────────────────────────────────
99.1 Press release, July 7, 2026
104 Cover Page Interactive Data File (embedded within the Inline XBRL Document)